NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Stock Price

NAMSStock

$19.83−45.63%52W

Market Cap$2.37B

P/E—

PEG Ratio—

Div yield—

Beta0.12

NAMS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-52.33%

Price vs S&P 500 (4W)-10.85%

VGM Score19.82

Book Value / Share (Quarterly)$5.37

P/TBV (Annual)5.82x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-38.66%

Cash Flow / Share (Quarterly)$0.04

Price vs S&P 500 (YTD)-55.40%

Net Profit Margin (TTM)-3644.21%

EPS (TTM)$-2.15

10-Day Avg Trading Volume1.36M

EPS Excl Extra (TTM)$-2.15

EPS (Annual)$-1.72

ROI (Annual)-29.82%

Cash / Share (Quarterly)$5.39

Revenue Growth QoQ (YoY)-80.67%

ROA (Last FY)-26.49%

Revenue Growth TTM (YoY)-88.87%

EBITD / Share (TTM)$-2.02

ROE (5Y Avg)-39.32%

Operating Margin (TTM)-3432.20%

Cash Flow / Share (Annual)$-1.29

P/B Ratio3.75x

P/B Ratio (Quarterly)6.27x

Net Income / Employee (Annual)$-2,038,200

EV / Revenue (TTM)273.31x

Net Interest Coverage (TTM)-6.44x

ROA (TTM)-34.68%

EPS Incl Extra (Annual)$-1.72

Current Ratio (Annual)7.88x

Quick Ratio (Quarterly)8.78x

3-Month Avg Trading Volume1.31M

52-Week Price Return-45.63%

Revenue / Employee (TTM)$71,200

Tangible BV / Share (Quarterly)$5.36

P/S Ratio (Annual)105.34x

Asset Turnover (Annual)0.03x

52-Week High$42.20

EPS Excl Extra (Annual)$-1.72

CapEx CAGR (5Y)89.75%

26-Week Price Return-42.42%

Quick Ratio (Annual)7.70x

13-Week Price Return-37.41%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.03x

Enterprise Value$1.95B

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$225,000

Pretax Margin (Annual)-905.74%

Cash / Share (Annual)$5.56

3-Month Return Std Dev50.55%

Net Income / Employee (TTM)$-2,595,000

ROE (Last FY)-29.82%

EPS Basic Excl Extra (Annual)$-1.72

P/FCF (TTM)20.19x

EV / Free Cash Flow (TTM)451.89x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.15

ROI (TTM)-38.33%

P/S Ratio (TTM)332.88x

Revenue / Share (Annual)$0.19

Tangible BV / Share (Annual)$5.97

Price vs S&P 500 (52W)-61.16%

Year-to-Date Return-43.47%

5-Day Price Return-6.68%

EPS Normalized (Annual)$-1.72

ROA (5Y Avg)-33.58%

Net Profit Margin (Annual)-905.74%

Month-to-Date Return-18.46%

Cash Flow / Share (TTM)$-0.26

EBITD / Share (Annual)$-1.90

Operating Margin (Annual)-1002.90%

P/CF (TTM)548.58x

ROI (5Y Avg)-39.27%

EPS Basic Excl Extra (TTM)$-2.15

P/TBV (Quarterly)6.28x

P/B Ratio (Annual)5.82x

Pretax Margin (TTM)-3644.21%

Book Value / Share (Annual)$5.97

Price vs S&P 500 (13W)-40.09%

Beta0.12x

P/FCF (Annual)297.79x

Revenue / Share (TTM)$0.06

ROE (TTM)-38.33%

52-Week Low$19.58

vGradeF

gGradeF

mGradeD

vgmGradeF

NAMS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.43	-$0.45	-5.70%(-$0.02)
Q1 2026	May 7, 2026	-$0.41	-$0.34	+16.50%(+$0.07)
Q4 2025	Feb 18, 2026	-$0.37	-$0.53	-45.31%(-$0.17)
Q3 2025	Nov 5, 2025	-$0.34	-$0.53	-54.04%(-$0.19)
Q2 2025	Aug 6, 2025	-$0.43	-$0.13	+69.85%(+$0.30)

NAMS Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.32

4.30

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares	F	F	D	332.9x	-88.9%	—	—	$19.83
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About NewAmsterdam Pharma Company N.V. Ordinary Shares

NewAmsterdam Pharma is a biopharmaceutical company developing therapies for cardio-metabolic diseases, focusing on patients where current treatments are inadequate or poorly tolerated. The company's lead candidate, obicetrapib, is an oral CETP inhibitor designed to lower LDL cholesterol and address limitations of existing LDL-lowering treatments.

NAMS Next Earnings Report

Report dateNov 4, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.44

Revenue estimate$6.41M

Also reporting on Nov 4, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

NAMS Insider Transactions

BuySep 14, 2026
DAVIDSON MICHAEL H
Chief Executive Officer
Shares: 10,000Value: $226,500
SellSep 4, 2026
SMITHER JOHN W
Director
Shares: 1,600Value: $40,512
SellAug 24, 2026
KASTELEIN JOHANNES JACOB PIETER
Officer and Director
Shares: 125,000Value: $3.36M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

NGVTIngevity CorporationChemicals
ADMAADMA Biologics, Inc.Biological Products
IOSPInnospec Inc.Chemicals
ROGRogers CorporationPlastics & Resins
CLDXCelldex Therapeutics, IncIn Vitro Diagnostics
VCELVericel CorporationBiological Products
BCRXBioCryst Pharmaceuticals IncBiological Products
MTXMinerals Technologies IncIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$19.58

High$42.20